Malignant transformation in melanocytes is associated with increased production of procoagulant microvesicles

Summary

Shedding of microvesicles (MVs) by cancer cells is implicated in a variety of biological effects, including the establishment of cancer-associated hypercoagulable states. However, the mechanisms underlying malignant transformation and the acquisition of procoagulant properties by tumour-derived MVs are poorly understood. Here we investigated the procoagulant and prothrombotic properties of MVs produced by a melanocyte-derived cell line (melan-a) as compared to its tumourigenic melanoma counterpart Tm1. Tumour cells exhibit a two-fold higher rate of MVs production as compared to melan-a. Melanoma MVs display greater procoagulant activity and elevated levels of the clotting initiator protein tissue factor (TF). On the other hand, tumour- and melanocyte- derived MVs expose similar levels of the procoagulant lipid phosphatidylserine, displaying identical abilities to support thrombin generation by the prothrombinase complex. By using an arterial thrombosis model, we observed that melanoma- but not melanocyte-derived MVs strongly accelerate thrombus formation in a TF-dependent manner, and accumulate at the site of vascular injury. Analysis of plasma obtained from melanoma-bearing mice showed the presence of MVs with a similar procoagulant pattern as compared to Tm1 MVs produced in vitro. Remarkably, flow-cytometric analysis demonstrated that 60% of ex vivo MVs are TF-positive and carry the melanoma-associated antigen, demonstrating its tumour origin. Altogether our data suggest that malignant transformation in melanocytes increases the production of procoagulant MVs, which may contribute for a variety of coagulation- related protumoural responses.

Keywords

Microvesicles - cancer - melanocyte transformation - thrombosis

• References

• 1 Rickles FR, Levine MN. Epidemiology of thrombosis in cancer. Acta Haematol 2001; 106: 6-12.
• 2 Mandala M, Ferretti G, Cremonesi M. et al. Venous thromboembolism and cancer: new issues for an old topic. Crit Rev Oncol Hematol 2003; 48: 65-80.
• 3 Hoffman R, Haim N, Brenner B. Cancer and thrombosis revisited. Blood Rev 2001; 15: 61-67.
• 4 Sorensen HT, Mellemkjaer L, Olsen JH. et al. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000; 343: 1846-1850.
• 5 White RH, Chew H, Wun T. Targeting patients for anticoagulant prophylaxis trials in patients with cancer: who is at highest risk?. Thromb Res 2007; 120 (Suppl. 02) S29-S40.
• 6 Rickles FR, Edwards RL. Activation of blood coagulation in cancer: Trousseau's syndrome revisited. Blood 1983; 62: 14-31.
• 7 Freyssinet JM. Cellular microparticles: what are they bad or good for?. J Thromb Haemost 2003; 1: 1655-1662.
• 8 Zwaal RF, Schroit AJ. Pathophysiologic implications of membrane phospholipid asymmetry in blood cells. Blood 1997; 89: 1121-1132.
• 9 Diamant M, Tushuizen ME, Sturk A. et al. Cellular microparticles: new players in the field of vascular disease?. Eur J Clin Invest 2004; 34: 392-401.
• 10 Aharon A, Brenner B. Microparticles, thrombosis and cancer. Best Pract Res Clin Haematol 2009; 22: 61-69.
• 11 Janowska-Wieczorek A, Wysoczynski M, Kijowski J. et al. Microvesicles derived from activated platelets induce metastasis and angiogenesis in lung cancer. Int J Cancer 2005; 113: 752-760.
• 12 Lima LG, Chammas R, Monteiro RQ. et al. Tumor-derived microvesicles modulate the establishment of metastatic melanoma in a phosphatidylserine-dependent manner. Cancer Lett 2009; 283: 168-175.
• 13 Hron G, Kollars M, Weber H. et al. Tissue factor-positive microparticles: cellular origin and association with coagulation activation in patients with colorectal cancer. Thromb Haemost 2007; 97: 119-123.
• 14 Langer F, Spath B, Haubold K. et al. Tissue factor procoagulant activity of plasma microparticles in patients with cancer-associated disseminated intravascular coagulation. Ann Hematol 2008; 87: 451-457.
• 15 Tesselaar ME, Romijn FP, van der Linden IK. et al. Microparticle-associated tissue factor activity: a link between cancer and thrombosis?. J Thromb Haemost 2007; 5: 520-527.
• 16 Zwicker JI, Liebman HA, Neuberg D. et al. Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy. Clin Cancer Res 2009; 15: 6830-6840.
• 17 Bastida E, Ordinas A, Escolar G. et al. Tissue factor in microvesicles shed from U87MG human glioblastoma cells induces coagulation, platelet aggregation, and thrombogenesis. Blood 1984; 64: 177-184.
• 18 Dvorak HF, Van DL, Bitzer AM. et al. Procoagulant activity associated with plasma membrane vesicles shed by cultured tumor cells. Cancer Res 1983; 43: 4434-4442.
• 19 Mueller BM, Reisfeld RA, Edgington TS. et al. Expression of tissue factor by melanoma cells promotes efficient hematogenous metastasis. Proc Natl Acad Sci USA 1992; 89: 11832-11836.
• 20 Yu JL, May L, Lhotak V. et al. Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. Blood 2005; 105: 1734-1741.
• 21 Kageshita T, Funasaka Y, Ichihashi M. et al. Differential expression of tissue factor and tissue factor pathway inhibitor in metastatic melanoma lesions. Pigment Cell Res 2002; 15: 212-216.
• 22 Kakkar AK, Lemoine NR, Scully MF. et al. Tissue factor expression correlates with histological grade in human pancreatic cancer. Br J Surg 1995; 82: 1101-1104.
• 23 Rak J, Milsom C, Magnus N. et al. Tissue factor in tumour progression. Best Pract Res Clin Haematol 2009; 22: 71-83.
• 24 Buller HR, van Doormaal FF, van Sluis GL. et al. Cancer and thrombosis: from molecular mechanisms to clinical presentations. J Thromb Haemost 2007; 5 (Suppl. 01) 246-254.
• 25 Khorana AA, Ahrendt SA, Ryan CK. et al. Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer. Clin Cancer Res 2007; 13: 2870-2875.
• 26 Thomas GM, Panicot-Dubois L, Lacroix R. et al. Cancer cell-derived microparticles bearing P-selectin glycoprotein ligand 1 accelerate thrombus formation in vivo. J Exp Med 2009; 206: 1913-1927.
• 27 Petersen LC, Norby PL, Branner S. et al. Characterization of recombinant murine factor VIIa and recombinant murine tissue factor: a human-murine species compatibility study. Thromb Res 2005; 116: 75-85.
• 28 Bennett DC, Cooper PJ, Hart IR. A line of non-tumorigenic mouse melanocytes, syngeneic with the B16 melanoma and requiring a tumour promoter for growth. Int J Cancer 1987; 39: 414-418.
• 29 Oba-Shinjo SM, Correa M, Ricca TI. et al. Melanocyte transformation associated with substrate adhesion impediment. Neoplasia 2006; 8: 231-241.
• 30 Lacroix R, Robert S, Poncelet P. et al. Standardization of platelet-derived microparticle enumeration by flow cytometry with calibrated beads: results of the International Society on Thrombosis and Haemostasis SSC Collaborative workshop. J Thromb Haemost 2010; 8: 2571-2574.
• 31 Ran S, He J, Huang X. et al. Antitumor effects of a monoclonal antibody that binds anionic phospholipids on the surface of tumor blood vessels in mice. Clin Cancer Res 2005; 11: 1551-1562.
• 32 Huang X, Bennett M, Thorpe PE. A monoclonal antibody that binds anionic phospholipids on tumor blood vessels enhances the antitumor effect of docetaxel on human breast tumors in mice. Cancer Res 2005; 65: 4408-4416.
• 33 Beck AW, Luster TA, Miller AF. et al. Combination of a monoclonal anti-phosphatidylserine antibody with gemcitabine strongly inhibits the growth and metastasis of orthotopic pancreatic tumors in mice. Int J Cancer 2006; 118: 2639-2643.
• 34 Luster TA, He J, Huang X. et al. Plasma protein beta-2-glycoprotein 1 mediates interaction between the anti-tumor monoclonal antibody 3G4 and anionic phospholipids on endothelial cells. J Biol Chem 2006; 281: 29863-29871.
• 35 Pickering W, Gray E, Goodall AH. et al. Effects of apoptosis and lipid peroxidation on T-lymphoblastoid phospholipid-dependent procoagulant activity. J Thromb Haemost 2008; 6: 1122-1130.
• 36 Fernandes RS, Kirszberg C, Rumjanek VM. et al. On the molecular mechanisms for the highly procoagulant pattern of C6 glioma cells. J Thromb Haemost 2006; 4: 1546-1552.
• 37 D'Amico G, Bonamino M, Dander E. et al. T cells stimulated by CD40L positive leukemic blasts-pulsed dendritic cells meet optimal functional requirements for adoptive T-cell therapy. Leukemia 2006; 20: 2015-2024.
• 38 He L, Vicente CP, Westrick RJ. et al. Heparin cofactor II inhibits arterial thrombosis after endothelial injury. J Clin Invest 2002; 109: 213-219.
• 39 Leong SPL, Muller J, Yetter RA. et al. Expression and modulation of a retrovirus-associated antigen by murine melanoma cells. Cancer Res 1988; 48: 4954-4958.
• 40 Correa M, Machado Jr. J, Carneiro CR. et al. Transient inflammatory response induced by apoptotic cells is an important mediator of melanoma cell engraftment and growth. Int J Cancer 2005; 114: 356-363.
• 41 Kirszberg C, Lima LG, Da Silva de OA. et al. Simultaneous tissue factor expression and phosphatidylserine exposure account for the highly procoagulant pattern of melanoma cell lines. Melanoma Res 2009; 19: 301-308.
• 42 Bromberg ME, Konigsberg WH, Madison JF. et al. Tissue factor promotes melanoma metastasis by a pathway independent of blood coagulation. Proc Natl Acad Sci USA 1995; 92: 8205-8209.
• 43 Wolf P. The nature and significance of platelet products in human plasma. Br J Haematol 1967; 13: 269-288.
• 44 Rak J. Microparticles in cancer. Semin Thromb Hemost 2010; 36: 888-906.
• 45 Ginestra A, La Placa MD, Saladino F. et al. The amount and proteolytic content of vesicles shed by human cancer cell lines correlates with their in vitro invasiveness. Anticancer Res 1998; 18: 3433-3437.
• 46 Taylor DD, Taylor CG, Jiang CG. et al. Characterization of plasma membrane shedding from murine melanoma cells. Int J Cancer 1988; 41: 629-635.
• 47 Al-Nedawi K, Meehan B, Micallef J. et al. Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. Nat Cell Biol 2008; 10: 619-624.
• 48 Yu JL, Rak JW. Shedding of tissue factor (TF)-containing microparticles rather than alternatively spliced TF is the main source of TF activity released from human cancer cells. J Thromb Haemost 2004; 2: 2065-2067.
• 49 Skog J, Wurdinger T, van RS. et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol 2008; 10: 1470-1476.
• 50 Davila M, Amirkhosravi A, Coll E. et al. Tissue factor-bearing microparticles derived from tumor cells: impact on coagulation activation. J Thromb Haemost 2008; 6: 1517-1524.
• 51 Nieuwland R. Cellular origin of microparticles exposing tissue factor in cancer: a mixed double?. J Thromb Haemost 2008; 6: 1514-1516.
• 52 Carneiro-Lobo TC, Konig S, Machado DE. et al. Ixolaris, a tissue factor inhibitor, blocks primary tumor growth and angiogenesis in a glioblastoma model. J Thromb Haemost 2009; 7: 1855-1864.
• 53 Versteeg HH, Schaffner F, Kerver M. et al. Inhibition of tissue factor signaling suppresses tumor growth. Blood 2008; 111: 190-199.
• 54 Tallman MS, Lefebvre P, Baine RM. et al. Effects of all-trans retinoic acid or chemotherapy on the molecular regulation of systemic blood coagulation and fibrinolysis in patients with acute promyelocytic leukemia. J Thromb Haemost 2004; 2: 1341-1350.